Esaxerenone

DB15207InvestigationalSmall molecule

Esaxerenone is under investigation in clinical trial NCT02722265 (Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension).

Mechanism: Pharmacologically active on Mineralocorticoid receptor
Curator reviewed
Formula / weight: C₂₂H₂₁F₃N₂O₄S · 466.48 g/mol (avg)
Code names: CS-3150 · XL-550

Resolves to

Compound

UNIIN62TGJ04A1CAS1632006-28-0ChEMBLCHEMBL2181932

Structure

InChIKeyNOSNHVJANRODGR-UHFFFAOYSA-NSMILESCC1=C(N(CCO)C=C1C(=O)NC1=CC=C(C=C1)S(C)(=O)=O)C1=C(C=CC=C1)C(F)(F)F

Targets

P08235NR3C2

What you can answer from here — as of August 29, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Esaxerenone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account